Presented today at #SABCS23 and published in @JAMA_current results of our study showing the feasibility and safety of #pregnancy after #BreastCancer in young #BRCA carriers @OncoAlert @SABCSSanAntonio @AACR @UniGenova @SanMartino_Ge #bcsm Link here: https://t.co/PqAAhVq2bO

Very interesting data, thanks for posting. Progestational agents are promoters. Brings up interesting questions about the potential for risk modification given the increasing rates of BC in young women. @OncoAlert @AnnPartridgeMD @matteolambe thoughts?

Full text link:

The #POSITIVE trial update presented by @fedrophd at #ESMO25 @myESMO confirms the safety of temporarily interrupting adjuvant ET to conceive. With @matteolambe in @NatRevClinOncol we proposed a practical approach balancing recurrence risk and patient preferences⚖️ @OncoAlert

"REGULATE" "LICENSES OR OTHERWISE" GAME OVER.

Nurses are the heart of healthcare — their compassion drives healing. Join the Oncology Nursing Session at #APBCS2026, supported by the @oncologynursing Society. Feb 7, 2026 | 08:30–13:00 MYT | Penang, Malaysia Register: https://t.co/GNtqt3fmRT #OncologyNursing #BreastCancer

New @Nature study shows how pregnancy + breastfeeding trigger CD8⁺ T-cell immunity in the breast. In a new interview, @LoiSher breaks down the mechanistic data linking parity > immune protection in TNBC. https://t.co/urKfaqQpmN @matteolambe @PTarantinoMD @PeterMacCC @Dr_RShatsky

Our #OncoAlertAF 🚨Colleague @GIMedOnc 🇺🇸 of @NorthwellHealth with his TOP picks of #GIOncology Trials Presented at #ESMO25 🇩🇪for the OncoAlert TOP3 Series post ESMO 2025, more to come.. ✅NICHE2 ✅STELLAR 303 @pashtoonkasi @CathyEngMD @marklewismd @AndresC27622123 @manjuggm

Excited to see our new publication! Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 ILD/pneumonitis in @Annals_Oncology Marked efficacy with reRx post recovery! @oncoalert @cityofhope

THE #ESMO25 COMPLETE Newsletter by OncoAlert 🚨MONDAY Nov 3rd is the FINAL DAY TO GET IT‼️ TO GET IT REGISTER at https://t.co/yzt83gqQkF OR https://t.co/dq8GEzl9ps 5⃣0⃣of our pick of TOP Trials Presented in Berlin🇩🇪 @matteolambe @christine_lovly @peters_solange @aftimosp

At ICONIQ Frontier, one question guided our conversations: What does it take to build at the frontier of AI? From @DarioAmodei to @drfeifei to @bradlightcap, a clear answer emerged amongst speakers: the most powerful force shaping AI isn’t technical. It’s human. How we lead,

Thank you @GileadSciences for helping us moving forward with our research and @VHIO for the trust and support💫 And now it’s time to get started 💪🏻💪🏻

F/56 yrs ,Early TNBC Pacli carbo x 12# weekly horrendous complications to chemo MRM - pCR Brca + WWYD 1) ddAC x 4 2) PARPi @OncBrothers @DrRishabhOnco @stolaney1 @PTarantinoMD @matteolambe @dr_yakupergun @UmutDisel @LoiSher @hoperugo @ndenduluri1

The OncoAlert TOP STACK: DESTINY Breast 09 T-DXd plus pertuzumab significantly improves outcomes versus THP across all subgroups of HER2-positive advanced or metastatic #BreastCancer , with a consistent safety profile. Included in this Stack Posts from: @VHIO @Onco_Cifu88

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer https://t.co/FV7ILxcUif This phase 3 trial evaluating first-line treatment for HER2-positive advanced or metastatic #BreastCancer , trastuzumab deruxtecan plus pertuzumab significantly improved

Please click onto the image to hear oldies and classic rock

Highly relevant data in @TheLancetOncol by the group of #FredericAmant for young women with #cancer diagnosed during #pregnancy on how to optimize the use of diagnostic imaging procedures in this challenging situation Link: https://t.co/bs34K1sywc @OncoAlert @KU_Leuven

Out in @Nature important data by the group of super @LoiSher from @PeterMacCC showing the potential molecular mechanisms behind the protection of #parity and #breastfeeding against #BreastCancer risk Link: https://t.co/5GfB3KOwRL @OncoAlert #bcsm

Dear Colleagues, Our @OncoAlert 🚨Faculty @ElisaAgostinett 🇧🇪of @JulesBordet with her TOP picks of #BreastCancer Trials Presented at #ESMO25 🇩🇪 for the OncoAlert TOP3 Series post ESMO, more to come.. ✅monarchE ✅NATALEE ✅Destiny Breast 05 ✅Destiny Breast 11 ✅ASCENT03

#INSIEME a @delmastro_lucia per @AIOMtweet 🎯🎯

We've been cooking something up in the studio. The @nvidiastudio that is, letting us create without limits.

Privilegiata ad essere parte della vostra squadra..e sempre #INSIEME a @delmastro_lucia @AIOMtweet @OncoAlert

THE #ESMO25 COMPLETE Newsletter by OncoAlert 🚨COMES OUT Monday October 27, 2025‼️ TO GET IT REGISTER at https://t.co/yzt83gqQkF OR https://t.co/dq8GEzl9ps 5⃣0⃣of our pick of TOP Trials Presented in Berlin🇩🇪 @matteolambe @christine_lovly @peters_solange @aftimosp

#Oncologia #Formazione #Ricerca #Mentorship #Eccellenza #AIOM #INSIEME

Insieme alla cura dei pazienti e alla ricerca, la formazione dei giovani oncologi è una delle componenti più belle del nostro lavoro. Quando il risultato sono eccellenze come Matteo Lambertini, si viene ripagati di tutto l’impegno e le energie investiti!

A New Dawn rises. Supernova marks the next evolution of the network. Engineered for speed, scale, and true decentralization. Five years ago, the first Battle of Nodes tested the limits before mainnet launch. An epic competition still remembered today. Now, the competition